ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 167,50
-0,26%
Dow Jones
40 003,59
0,34%
DAX
18 704,42
-0,11%
Brent Oil
83,76
0,00%
Bitcoin
66 990,47
0,07%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. REGENXBIO Inc (RGNX)

  7. REGENXBIO Inc (RGNX) Actualités

RGNX

REGENXBIO (RGNX)

REGENXBIO Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:RGNX
DateHeureSourceTitreSymboleSociété
16/05/202423h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGNXREGENXBIO Inc
14/05/202422h22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RGNXREGENXBIO Inc
10/05/202413h05PR Newswire (US)REGENXBIO to Participate in Upcoming Investor ConferencesNASDAQ:RGNXREGENXBIO Inc
08/05/202422h16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RGNXREGENXBIO Inc
08/05/202422h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RGNXREGENXBIO Inc
08/05/202422h05PR Newswire (US)REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational HighlightsNASDAQ:RGNXREGENXBIO Inc
01/05/202413h05PR Newswire (US)REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational HighlightsNASDAQ:RGNXREGENXBIO Inc
24/04/202413h05PR Newswire (US)REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitNASDAQ:RGNXREGENXBIO Inc
28/03/202412h05PR Newswire (US)REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMDNASDAQ:RGNXREGENXBIO Inc
27/03/202421h05PR Newswire (US)REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy DaysNASDAQ:RGNXREGENXBIO Inc
08/03/202412h09Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RGNXREGENXBIO Inc
07/03/202412h03Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:RGNXREGENXBIO Inc
07/03/202405h20PR Newswire (US)REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded WarrantsNASDAQ:RGNXREGENXBIO Inc
06/03/202422h10PR Newswire (US)REGENXBIO Announces Proposed Public Offering of Common StockNASDAQ:RGNXREGENXBIO Inc
05/03/202413h05PR Newswire (US)REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIALNASDAQ:RGNXREGENXBIO Inc
29/02/202422h57PR Newswire (US)REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® TrialNASDAQ:RGNXREGENXBIO Inc
27/02/202422h54Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RGNXREGENXBIO Inc
27/02/202422h05PR Newswire (US)REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational HighlightsNASDAQ:RGNXREGENXBIO Inc
21/02/202413h05PR Newswire (US)REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational HighlightsNASDAQ:RGNXREGENXBIO Inc
07/02/202417h40PR Newswire (US)REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary EndpointNASDAQ:RGNXREGENXBIO Inc
07/02/202413h05PR Newswire (US)REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® TrialNASDAQ:RGNXREGENXBIO Inc
31/01/202413h05PR Newswire (US)REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024NASDAQ:RGNXREGENXBIO Inc
16/01/202420h47PR Newswire (US)REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal DeliveryNASDAQ:RGNXREGENXBIO Inc
10/01/202413h05PR Newswire (US)REGENXBIO Announces Presentation at the Hawaiian Eye and Retina 2024 MeetingNASDAQ:RGNXREGENXBIO Inc
08/01/202413h05PR Newswire (US)U.S. District Court Issues Decision on REGENXBIO and University of Pennsylvania NAV® Technology Patent Infringement LawsuitNASDAQ:RGNXREGENXBIO Inc
29/11/202313h05PR Newswire (US)REGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® TrialNASDAQ:RGNXREGENXBIO Inc
08/11/202322h05PR Newswire (US)REGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial ResultsNASDAQ:RGNXREGENXBIO Inc
03/11/202323h53PR Newswire (US)REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal DeliveryNASDAQ:RGNXREGENXBIO Inc
01/11/202312h05PR Newswire (US)REGENXBIO to Host Conference Call on November 8 to Discuss Third Quarter 2023 Financial Results and Recent Operational HighlightsNASDAQ:RGNXREGENXBIO Inc
30/10/202312h05PR Newswire (US)REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2023 Annual MeetingNASDAQ:RGNXREGENXBIO Inc
 Showing the most relevant articles for your search:NASDAQ:RGNX

Dernières Valeurs Consultées

ASX
FXLKOD
AMEX
LCR
Leuthold Core ETF
COIN
KKCGBP
ASX
VRE
View Resources
NASDAQ
STRUX
Stepstone Private Infras...
LSE
93HJ
Saudi.araba 39r
LATK
LMABTC
Lamoneda
USOTC
HSHCY
Haier Smart Home (PK)
EU
GSPDF
Funds
COIN
SIXNUSD
EU
STT
Spdr Msci Europe Communi...
LSE
NGP
Niche Group
BIT
UC2DQV
Unicredit Bank
NYSE
CHAI
ETF Series Solut
NASDAQ
ZLSWW
Zalatoris II Acquisition
NASDAQ
AAYJJXX
Hsbc Usa Inc Point to Po...
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés